(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
4 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 7.63%
@ $43.42
Išleistas: 8 bal. 2024 @ 16:30
Grąža: -4.20%
Ankstesnis signalas: bal. 4 - 19:17
Ankstesnis signalas:
Grąža: 0.06 %
Live Chart Being Loaded With Signals
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy...
Stats | |
---|---|
Šios dienos apimtis | 540 395 |
Vidutinė apimtis | 1.07M |
Rinkos kapitalizacija | 6.06B |
EPS | $0 ( 2024-02-21 ) |
Kita pelno data | ( $-1.070 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -16.25 |
ATR14 | $0.0240 (0.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Baroldi Joseph | Sell | 10 838 | Restricted Stock Unit |
2024-04-15 | Baroldi Joseph | Buy | 10 838 | Common Stock |
2024-04-16 | Baroldi Joseph | Sell | 4 006 | Common Stock |
2024-04-15 | Birchler Brian | Buy | 1 875 | Common Stock |
2024-04-16 | Birchler Brian | Sell | 905 | Common Stock |
INSIDER POWER |
---|
45.60 |
Last 100 transactions |
Buy: 1 051 999 | Sell: 391 277 |
Tūris Koreliacija
Ionis Pharmaceuticals Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
ALVR | 0.928 |
BGFV | 0.913 |
GRNA | 0.902 |
INFI | 0.897 |
CARE | 0.895 |
CMCT | 0.893 |
GBCI | 0.889 |
EQ | 0.889 |
BIOC | 0.885 |
CRBU | 0.882 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
STAY | -0.908 |
TRMD | -0.878 |
BCOR | -0.875 |
PAYA | -0.873 |
IBEX | -0.868 |
PDFS | -0.867 |
BNIXU | -0.866 |
TGLS | -0.865 |
LRFC | -0.865 |
ARDX | -0.861 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Ionis Pharmaceuticals Inc Koreliacija - Valiuta/Žaliavos
Ionis Pharmaceuticals Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $787.65M |
Bruto pelnas: | $778.51M (98.84 %) |
EPS: | $-2.56 |
FY | 2023 |
Pajamos: | $787.65M |
Bruto pelnas: | $778.51M (98.84 %) |
EPS: | $-2.56 |
FY | 2022 |
Pajamos: | $587.00M |
Bruto pelnas: | $573.00M (97.61 %) |
EPS: | $-1.900 |
FY | 2021 |
Pajamos: | $810.46M |
Bruto pelnas: | $799.61M (98.66 %) |
EPS: | $-0.200 |
Financial Reports:
No articles found.
Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.